Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics
- 1 June 2017
- journal article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 86, 221-230
- https://doi.org/10.1016/j.yrtph.2017.03.013
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Good news–bad news: the Yin and Yang of immune privilege in the eyeFrontiers in Immunology, 2012
- The privileged immunity of immune privileged organs: the case of the eyeFrontiers in Immunology, 2012
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Ocular Inflammation in Cynomolgus Macaques Following Intravenous Administration of a Human Monoclonal AntibodyInternational Journal of Toxicology, 2009
- Mechanisms of leukocyte migration across the blood–retina barrierSeminars in Immunopathology, 2008
- Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical ConsiderationsToxicologic Pathology, 2008
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITSRetina, 2007
- Current Treatment of Age-Related Macular DegenerationOptometry and Vision Science, 2007
- Granulomatous inflammation--a review.Journal of Clinical Pathology, 1983
- Immune response evoked by antigen injection in the rabbit vitreous combined with immunopotentiationAlbrecht von Graefes Archiv für Ophthalmologie, 1981